[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 56, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 57, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.72, "open": 1.73, "dayLow": 1.694, "dayHigh": 1.78, "regularMarketPreviousClose": 1.72, "regularMarketOpen": 1.73, "regularMarketDayLow": 1.694, "regularMarketDayHigh": 1.78, "payoutRatio": 0.0, "beta": 0.885, "forwardPE": -4.095238, "volume": 3262987, "regularMarketVolume": 3262987, "averageVolume": 2069841, "averageVolume10days": 1571400, "averageDailyVolume10Day": 1571400, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 352603456, "fiftyTwoWeekLow": 1.19, "fiftyTwoWeekHigh": 4.32, "priceToSalesTrailing12Months": 42.314106, "fiftyDayAverage": 1.6592, "twoHundredDayAverage": 2.152475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 277125792, "profitMargins": 0.0, "floatShares": 128554473, "sharesOutstanding": 205002000, "sharesShort": 25530638, "sharesShortPriorMonth": 24081792, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.1245, "heldPercentInsiders": 0.18337, "heldPercentInstitutions": 0.82142997, "shortRatio": 12.8, "shortPercentOfFloat": 0.16430001, "impliedSharesOutstanding": 205002000, "bookValue": 0.349, "priceToBook": 4.9283667, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -89298000, "trailingEps": -0.36, "forwardEps": -0.42, "enterpriseToRevenue": 33.256, "enterpriseToEbitda": -3.246, "52WeekChange": -0.19248825, "SandP52WeekChange": 0.09506309, "quoteType": "EQUITY", "currentPrice": 1.72, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.55, "targetMedianPrice": 7.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 10, "totalCash": 139036000, "totalCashPerShare": 0.678, "ebitda": -85376000, "totalDebt": 63559000, "quickRatio": 5.301, "currentRatio": 5.419, "totalRevenue": 8333000, "debtToEquity": 88.863, "revenuePerShare": 0.033, "returnOnAssets": -0.32506, "returnOnEquity": -1.2194, "grossProfits": 8333000, "freeCashflow": -48153876, "operatingCashflow": -81225000, "revenueGrowth": -0.439, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -9.857571, "financialCurrency": "USD", "symbol": "TSHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.72, "messageBoardId": "finmb_665948579", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "corporateActions": [], "postMarketTime": 1741995870, "regularMarketTime": 1741982401, "exchange": "NMS", "market": "us_market", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1600954200000, "postMarketChangePercent": 3.45349, "postMarketPrice": 1.7794, "postMarketChange": 0.0594, "regularMarketChange": 0.0, "regularMarketDayRange": "1.694 - 1.78", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2069841, "fiftyTwoWeekLowChange": 0.53, "fiftyTwoWeekLowChangePercent": 0.4453781, "fiftyTwoWeekRange": "1.19 - 4.32", "fiftyTwoWeekHighChange": -2.6000001, "fiftyTwoWeekHighChangePercent": -0.6018519, "fiftyTwoWeekChangePercent": -19.248825, "earningsTimestamp": 1740574800, "earningsTimestampStart": 1747080000, "earningsTimestampEnd": 1747425600, "earningsCallTimestampStart": 1740576600, "earningsCallTimestampEnd": 1740576600, "isEarningsDateEstimate": true, "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "epsTrailingTwelveMonths": -0.36, "epsForward": -0.42, "epsCurrentYear": -0.38, "priceEpsCurrentYear": -4.5263157, "fiftyDayAverageChange": 0.060800076, "fiftyDayAverageChangePercent": 0.036644213, "twoHundredDayAverageChange": -0.4324751, "twoHundredDayAverageChangePercent": -0.2009199, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-09-24", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "Taysha Gene Therapies", "trailingPegRatio": null, "__fetch_time": "2025-03-15"}]